Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

118.10 -1.53 (-1.28%)
Official Closing Price Updated: 7:00 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
News headline image
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
News headline image
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere ↗
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
News headline image
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
News headline image
Price Over Earnings Overview: Merck & Co ↗
 
Via Benzinga
News headline image
2 Reasons to Watch MRK and 1 to Stay Cautious
Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move. 
Via StockStory
Topics Supply Chain
News headline image
Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake ↗
Healthcare stocks are lagging the market by the widest margin since 2008. Analysts and valuation trends point to a rebound. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals ↗
MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors. 
Via Chartmill
News headline image
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Dividend Stocks to Buy and Never Sell ↗
Via The Motley Fool
Topics Lawsuit
News headline image
3 Mega-Cap Stocks with Competitive Advantages
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
News headline image
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills ↗
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
News headline image
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 ↗
The Dow Jones index could have fared better in May if not for these two stocks. 
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
News headline image
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
News headline image
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish ↗
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said. 
Via Stocktwits
Topics Death
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
News headline image
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit ↗
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine. 
Via Benzinga
Topics Lawsuit
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗
Via The Motley Fool
Topics Artificial Intelligence Government
News headline image
Unpacking the Latest Options Trading Trends in Merck & Co ↗
 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals ↗
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors. 
Via Chartmill
News headline image
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials ↗
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported. 
Via Benzinga
News headline image
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish ↗
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide. 
Via Stocktwits
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Top S&P500 movers in Monday's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.